BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 33058912)

  • 1. Upregulated mH2A1 serves as an unfavorable prognostic indicator and promotes the progress of hepatocellular carcinoma (HCC).
    Yang G; Yao Y; Wu D; Guo H; Zhou S; Sun D; Guo X; Zheng T; Wang J; Zhang S; Wang Y; Song R; Ke S; Liu Y; Meng F; Liang Y; Lu Z; Liu L
    Life Sci; 2020 Dec; 263():118576. PubMed ID: 33058912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UCK2 upregulation might serve as an indicator of unfavorable prognosis of hepatocellular carcinoma.
    Yu S; Li X; Guo X; Zhang H; Qin R; Wang M
    IUBMB Life; 2019 Jan; 71(1):105-112. PubMed ID: 30304569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zinc finger protein ZBTB20 is an independent prognostic marker and promotes tumor growth of human hepatocellular carcinoma by repressing FoxO1.
    Kan H; Huang Y; Li X; Liu D; Chen J; Shu M
    Oncotarget; 2016 Mar; 7(12):14336-49. PubMed ID: 26893361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma.
    Wang F; Feng Y; Li P; Wang K; Feng L; Liu YF; Huang H; Guo YB; Mao QS; Xue WJ
    Oncotarget; 2016 Jan; 7(4):4279-97. PubMed ID: 26701853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hornerin promotes tumor progression and is associated with poor prognosis in hepatocellular carcinoma.
    Fu SJ; Shen SL; Li SQ; Hua YP; Hu WJ; Guo B; Peng BG
    BMC Cancer; 2018 Aug; 18(1):815. PubMed ID: 30103712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylation-mediated repression of microRNA-129-2 suppresses cell aggressiveness by inhibiting high mobility group box 1 in human hepatocellular carcinoma.
    Liu Z; Dou C; Yao B; Xu M; Ding L; Wang Y; Jia Y; Li Q; Zhang H; Tu K; Song T; Liu Q
    Oncotarget; 2016 Jun; 7(24):36909-36923. PubMed ID: 27191994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long noncoding RNA GIHCG promotes hepatocellular carcinoma progression through epigenetically regulating miR-200b/a/429.
    Sui CJ; Zhou YM; Shen WF; Dai BH; Lu JJ; Zhang MF; Yang JM
    J Mol Med (Berl); 2016 Nov; 94(11):1281-1296. PubMed ID: 27380494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma.
    Wang J; Xia C; Pu M; Dai B; Yang X; Shang R; Yang Z; Zhang R; Tao K; Dou K
    Oncol Rep; 2018 Oct; 40(4):1875-1884. PubMed ID: 30015982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and prognostic significance of epithelial tissue-specific transcription factor ESE3 in hepatocellular carcinoma.
    Lyu Z; Ma M; Xu Y; Wang X; Zhu Y; Ren W; Li T
    Int J Clin Oncol; 2020 Jul; 25(7):1334-1345. PubMed ID: 32347431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
    Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
    Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uridine-cytidine kinase 2 upregulation predicts poor prognosis of hepatocellular carcinoma and is associated with cancer aggressiveness.
    Huang S; Li J; Tam NL; Sun C; Hou Y; Hughes B; Wang Z; Zhou Q; He X; Wu L
    Mol Carcinog; 2019 Apr; 58(4):603-615. PubMed ID: 30556610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
    Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
    J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRIM59 promotes tumor growth in hepatocellular carcinoma and regulates the cell cycle by degradation of protein phosphatase 1B.
    Ying H; Ji L; Xu Z; Fan X; Tong Y; Liu H; Zhao J; Cai X
    Cancer Lett; 2020 Mar; 473():13-24. PubMed ID: 31875525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HUS1 checkpoint clamp component (HUS1) is a potential tumor suppressor in primary hepatocellular carcinoma.
    Zhou ZQ; Zhao JJ; Chen CL; Liu Y; Zeng JX; Wu ZR; Tang Y; Zhu Q; Weng DS; Xia JC
    Mol Carcinog; 2019 Jan; 58(1):76-87. PubMed ID: 30182378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA methylation profiling identifies EYA4 gene as a prognostic molecular marker in hepatocellular carcinoma.
    Hou X; Peng JX; Hao XY; Cai JP; Liang LJ; Zhai JM; Zhang KS; Lai JM; Yin XY
    Ann Surg Oncol; 2014 Nov; 21(12):3891-9. PubMed ID: 24306662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long non-coding RNA UC001kfo promotes hepatocellular carcinoma proliferation and metastasis by targeting α-SMA.
    Pan Y; Qin T; Yin S; Zhang X; Gao X; Mu L
    Biomed Pharmacother; 2017 Mar; 87():669-677. PubMed ID: 28088733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of IQGAP3 in metastasis and epithelial-mesenchymal transition in human hepatocellular carcinoma.
    Shi Y; Qin N; Zhou Q; Chen Y; Huang S; Chen B; Shen G; Jia H
    J Transl Med; 2017 Aug; 15(1):176. PubMed ID: 28810875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of PRAME Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma Through the Activation of P53 Mediated Pathway.
    Zhu H; Wang J; Yin J; Lu B; Yang Q; Wan Y; Jia C
    Cell Physiol Biochem; 2018; 45(3):1121-1135. PubMed ID: 29439259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and biological significance of transcription termination factor, RNA polymerase I in human liver hepatocellular carcinoma.
    Komatsu H; Iguchi T; Ueda M; Nambara S; Saito T; Hirata H; Sakimura S; Takano Y; Uchi R; Shinden Y; Eguchi H; Masuda T; Sugimachi K; Eguchi H; Doki Y; Mori M; Mimori K
    Oncol Rep; 2016 Apr; 35(4):2073-80. PubMed ID: 26821084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.